Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess Sells 2,940 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 2,940 shares of the company’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $53.13, for a total value of $156,202.20. Following the sale, the director now owns 18,173 shares of the company’s stock, valued at $965,531.49. This trade represents a 13.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Robert Chess also recently made the following trade(s):

• On Tuesday, January 7th, Robert Chess sold 5,000 shares of Twist Bioscience stock. The stock was sold at an average price of $50.00, for a total value of $250,000.00.
• On Thursday, December 5th, Robert Chess sold 3,504 shares of Twist Bioscience stock. The stock was sold at an average price of $51.85, for a total value of $181,682.40.

Twist Bioscience Stock Down 5.0 %

Shares of TWST stock opened at $46.20 on Wednesday. The stock’s 50-day simple moving average is $48.79 and its 200-day simple moving average is $45.99. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.54 and a current ratio of 4.96. The firm has a market capitalization of $2.76 billion, a PE ratio of -13.67 and a beta of 1.87. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company’s revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.75) earnings per share. Equities analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TWST has been the subject of a number of analyst reports. Robert W. Baird upped their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. Barclays reduced their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 19th. Scotiabank upped their target price on Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a research report on Tuesday, February 4th. Wolfe Research began coverage on Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Finally, TD Cowen reaffirmed a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $53.80.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Van ECK Associates Corp increased its holdings in shares of Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in Twist Bioscience during the third quarter worth about $34,000. Signaturefd LLC grew its holdings in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares during the period. US Bancorp DE grew its holdings in Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after acquiring an additional 601 shares during the period. Finally, Beaird Harris Wealth Management LLC acquired a new stake in Twist Bioscience during the third quarter worth about $95,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.